Gluten for Autism Spectrum Disorders
Primary Purpose
Autism Spectrum Disorders
Status
Unknown status
Phase
Not Applicable
Locations
Poland
Study Type
Interventional
Intervention
Gluten challenge
Sponsored by
About this trial
This is an interventional treatment trial for Autism Spectrum Disorders
Eligibility Criteria
Inclusion Criteria:
- Children aged 3-5 and 11/12 years with a diagnosis of ASD
- GFD for at least 8 weeks prior to enrollment
- Minimal scores of 15 on SCQ
- Minimal scores 70 points on Leiter scale
- Consent of caregivers to participate in the study
Exclusion Criteria:
- Gluten-mediated disease (celiac disease, wheat allergy)
- Lack of motivation / opportunity to follow a diet
- Malnutrition (defined according World Health Organization - WHO standards as weight for height <-2 SDS - Standard Deviation Scores)
Sites / Locations
- Medical University of WarsawRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
A - gluten challenge group
B - gluten-free diet
Arm Description
Gluten challenge group - recommended daily intake of at least one normal meal containing gluten such as bread, pita, pasta, biscuits.
Continuation of GFD.
Outcomes
Primary Outcome Measures
The extent of autistic symptoms based on the Autism Diagnostic Observation Schedule - 2 (ADOS-2)
Secondary Outcome Measures
The severity of symptoms based on a Social Communication Questionnaire (SCQ)
Presentation of gastrointestinal (GI) functional disorders (evaluation based on a parent-report form - Rome III diagnostic questionnaire
The extent of adaptive level of functioning on Vineland Adaptive Behavior Scale (VABS)
The extent of functioning on Autism Spectrum Rating Scale (ASRS)
Anthropometry
Weight, height based on WHO growth charts, comparison of a ratio of weight for height (WfH), and body mass index (BMI)
Intelligence test Leiter International Performance Scale
Full Information
NCT ID
NCT02280746
First Posted
October 29, 2014
Last Updated
October 29, 2014
Sponsor
Medical University of Warsaw
Collaborators
Nutricia Foundation
1. Study Identification
Unique Protocol Identification Number
NCT02280746
Brief Title
Gluten for Autism Spectrum Disorders
Official Title
Gluten Dietary Intervention for Autistic Symptoms in Children With Autism Spectrum Disorders - Randomized Open Trial
Study Type
Interventional
2. Study Status
Record Verification Date
October 2014
Overall Recruitment Status
Unknown status
Study Start Date
September 2014 (undefined)
Primary Completion Date
December 2015 (Anticipated)
Study Completion Date
December 2015 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medical University of Warsaw
Collaborators
Nutricia Foundation
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
BACKGRUOUND: Autism spectrum disorder (ASD) is a common condition. The etiology of ASD remains unknown. Recent studies suggest a link between elimination diets and severity of autistic symptoms. The possible effects of a gluten-free diet (GFD) on symptoms remain unknown.
AIM: The aim of the study is to evaluate the impact of gluten challenge on the autistic symptoms in children with autism spectrum disorders (ASD) and on a gluten-free diet (GFD) in comparison to individuals continuing GFD.
METHODS: 70 children with ASD aged 3-5 and 11/12 remaining on GFD for at least 8 weeks will be randomly assigned to gluten-free and gluten-challenge diet.
Detailed Description
Autism Spectrum Disorder (ASD) is a neurodevelopmental lifelong disorder, significantly impairing the quality of life of patients and their families. The symptoms are thought to result from interaction between genetics and environment. Treatment is multidisciplinary, based on behavioral therapy, education, and sometimes requires specialized care (i.e. genetics) and pharmacotherapy. The lack of consensus about the etiology of ASD directs researchers to define the condition as combination of symptoms, patient's history data, the impact of co-morbidities (including gastrointestinal disorders), and the effectiveness of various management therapies.
The use of complementary and alternative methods (CAM) of treatment is common and includes especially elimination diets, which are intended to minimize symptoms. The basis for the potentially beneficial impact of dietary intervention has been reported in connection to the correlation between congenital metabolic disorders (phenylketonuria) in patients with ASD and improvements in their overt symptoms in patients with schizophrenia Excessive activity of peptides derived from the metabolism of gluten and casein in individuals with ASD is thought to result in impaired neurotransmission in the brain. The increased permeability of the intestinal barrier, resulting from the inflammatory response (the theory of "leaky gut") in ASD patients, simultaneously promotes excessive absorption of those compounds. Another hypothesis assumes the effectiveness of elimination diets in children with ASD, suggesting allergic background of neuropsychiatric symptoms. Additionally it is emphasized that the lack of ability to communicate symptoms or atypical clinical manifestations (i.e. neuropsychiatric symptoms like hyperactivity, sleep disorders) in children with ASD can make the diagnosis of gastrointestinal symptoms, allergy and other symptoms particularly difficult. Moreover the pain or discomfort may increase the risk of behavioral symptoms.
Review of the literature concerning the effectiveness of gluten-free and casein-free diet (GFCFD) in individuals with ASD reveals a possible bias of the available studies and lack of a definite conclusion. Among 35 identified studies only two randomized controlled trials have been analyzed. The data/information on reported effectiveness of interventions in the behavioral symptoms [mean difference (MD-mean difference) -5.60, 95% CI -9.02 to -2.18, p = 0.001] in Knivsberg's study, is not reliable because of study limitations. Whiteley et al summarized in 2012 the positive effect of GFCFD on various symptoms in ASD patients. However the influence of GFCFD in ASD children can be defined mostly as suggestive because of the methodological limitations. The main biases include: small sample size, unclear process of randomization and allocation, use of different ASD assessment tools, short trial duration, lack of evaluation of patients' compliance to intervention, and other limitations.
The theory of excessive activity of exogenous opioids reports on specific allergies (gluten and casein) suggesting a connection with celiac disease (CD) in subjects with ASD and thus providing a rationale to determine the effect of gluten on gastrointestinal symptoms and consequently on potential behavioral changes in this group of patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Autism Spectrum Disorders
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
70 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
A - gluten challenge group
Arm Type
Experimental
Arm Description
Gluten challenge group - recommended daily intake of at least one normal meal containing gluten such as bread, pita, pasta, biscuits.
Arm Title
B - gluten-free diet
Arm Type
No Intervention
Arm Description
Continuation of GFD.
Intervention Type
Other
Intervention Name(s)
Gluten challenge
Intervention Description
Intervention will be continued for at least 6 months
Primary Outcome Measure Information:
Title
The extent of autistic symptoms based on the Autism Diagnostic Observation Schedule - 2 (ADOS-2)
Time Frame
Change over time - 6 months
Secondary Outcome Measure Information:
Title
The severity of symptoms based on a Social Communication Questionnaire (SCQ)
Time Frame
Change over time - 6 months
Title
Presentation of gastrointestinal (GI) functional disorders (evaluation based on a parent-report form - Rome III diagnostic questionnaire
Time Frame
Before, after 12 weeks and at the end of intervention
Title
The extent of adaptive level of functioning on Vineland Adaptive Behavior Scale (VABS)
Time Frame
Change over time - 6 months
Title
The extent of functioning on Autism Spectrum Rating Scale (ASRS)
Time Frame
Change over time - 6 months
Title
Anthropometry
Description
Weight, height based on WHO growth charts, comparison of a ratio of weight for height (WfH), and body mass index (BMI)
Time Frame
Change over time - 6 months
Title
Intelligence test Leiter International Performance Scale
Time Frame
Change over time - 6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
3 Years
Maximum Age & Unit of Time
6 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Children aged 3-5 and 11/12 years with a diagnosis of ASD
GFD for at least 8 weeks prior to enrollment
Minimal scores of 15 on SCQ
Minimal scores 70 points on Leiter scale
Consent of caregivers to participate in the study
Exclusion Criteria:
Gluten-mediated disease (celiac disease, wheat allergy)
Lack of motivation / opportunity to follow a diet
Malnutrition (defined according World Health Organization - WHO standards as weight for height <-2 SDS - Standard Deviation Scores)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Anna Piwowarczyk
Phone
+48224523309
Email
piwowarczyk.ann@gamil.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrea Horvath
Organizational Affiliation
Medical University of Warsaw
Official's Role
Study Director
Facility Information:
Facility Name
Medical University of Warsaw
City
Warsaw
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anna Piwowarczyk
Phone
+48224523309
Email
piwowarczyk.ann@gmail.com
12. IPD Sharing Statement
Citations:
PubMed Identifier
31659595
Citation
Piwowarczyk A, Horvath A, Pisula E, Kawa R, Szajewska H. Gluten-Free Diet in Children with Autism Spectrum Disorders: A Randomized, Controlled, Single-Blinded Trial. J Autism Dev Disord. 2020 Feb;50(2):482-490. doi: 10.1007/s10803-019-04266-9.
Results Reference
derived
Learn more about this trial
Gluten for Autism Spectrum Disorders
We'll reach out to this number within 24 hrs